1-(3-(Dibenzylamino)phenyl)ethanone | 251966-49-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 1-(3-(Dibenzylamino)phenyl)ethanone
• 英文别名: 1-[3-(dibenzylamino)phenyl]ethanone
• CAS: 251966-49-1
• 化学式: C₂₂H₂₁NO
• 分子量: 315.415
• InChiKey: LUTIGZASJSAWFV-UHFFFAOYSA-N

物化性质

• 沸点：
  497.1±45.0 °C(Predicted)
• 密度：
  1.125±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.7
• 重原子数：
  24
• 可旋转键数：
  6
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  20.3
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  草酸二甲酯 、 1-(3-(Dibenzylamino)phenyl)ethanone 在 sodium t-butanolate 作用下， 以 四氢呋喃 、 乙二醇二甲醚 为溶剂， 反应 1.5h， 生成
  参考文献：
  名称：

  Targeting Inactive Enzyme Conformation: Aryl Diketoacid Derivatives as a New Class of PTP1B Inhibitors

  摘要：

  There has been considerable interest in protein tyrosine phosphatase 1B (PTP1B) as a therapeutic target for diabetes, obesity, as well as cancer. Identifying inhibitory compounds with good bioavailability is a major challenge of drug discovery programs targeted toward PTPs. Most current PTP active site-directed pharmacophores are negatively charged pTyr mimetics which cannot readily enter the cell. This lack of cell permeability limits the utility of such compounds in signaling studies and further therapeutic development. We identify aryl diketoacids as novel pTyr surrogates and show that neutral amide-linked aryl diketoacid dimers also exhibit excellent PTP inhibitory activity. Kinetic studies establish that these aryl diketoacid derivatives act as noncompetitive inhibitors of PTP1B. Crystal structures of ligand-bound PTP1B reveal that both the aryl diketoacid and its dimeric derivative bind PTP1B at the active site, albeit with distinct modes of interaction, in the catalytically inactive, WPD loop open conformation. Furthermore, dimeric aryl diketoacids are cell permeable and enhance insulin signaling in hepatoma cells, suggesting that targeting the inactive conformation may provide a unique opportunity for creating active site-directed PTP1B inhibitors with improved pharmacological properties.

  DOI：

  10.1021/ja8068177

文献信息

• Novel dimeric aryldiketo containing inhibitors of HIV-1 integrase: Effects of the phenyl substituent and the linker orientation
  作者：Li-Fan Zeng、Xiao-Hua Jiang、Tino Sanchez、Hu-Shan Zhang、Raveendra Dayam、Nouri Neamati、Ya-Qiu Long

  DOI：10.1016/j.bmc.2008.07.008

  日期：2008.8

  a further structure-activity relationship (SAR) study with respect to the substituent effect of the ADK and the dimerization with conformationally constrained linkers such as piperazine, 4-amino-piperidine, piperidin-4-ol, and trans-cyclohexan-1,4-diamine. The substituents on the phenyl ring as well as the spatial orientation of the two diketo units were observed to play important roles in the IN inhibitory

  芳基二酮酸（ADK）及其生物等排体是最有希望的HIV-1整合酶（IN）抑制剂。以前，我们设计了一系列ADK二聚体作为一类新的IN抑制剂，假设它们靶向IN活性位点上的两个二价金属离子。本文中，我们针对ADK的取代作用以及构象受限的连接基（例如哌嗪，4-氨基-哌啶，哌啶丁-4-醇和反式环己基-二聚体）的二聚化，提出了进一步的结构活性关系（SAR）研究。 1,4-二胺。观察到苯环上的取代基以及两个二酮单元的空间取向在IN抑制能力中起重要作用。疏水基团是在芳基环的3位上的最佳取代。哌嗪和4-氨基-哌啶连接基带来了疏水基团或卤素取代的ADK二聚体中最有效的类似物。对接研究表明，在3-苯环上的大量疏水取代和4-氨基-哌啶的连接体有利于采用一种活性构象，以实现与活性位点Mg（2+）和其中的关键残基E152的强相互作用。催化核心结构域。这项研究是我们先前关于含二聚体ADK的IN抑制剂的报告的重要扩展，为进
• Single-step conversion of N-benzyl, N-trityl and N-diphenylmethyl amines to t-butyl carbamates using polymethylhydrosiloxane
  作者：S. Chandrasekhar、B.Nagendra Babu、Ch.Raji Reddy

  DOI：10.1016/s0040-4039(03)00172-2

  日期：2003.3

  t-Butyl carbamates were obtained efficiently in high yields from the corresponding N-benzyl, N-trityl and N-diphenylmethyl precursors in a single-step reductive transformation employing polymethylhydrosiloxane and di-t-butyl dicarbonate under Pd(OH)(2)/C catalysis. (C) 2003 Elsevier Science Ltd. All rights reserved.
• ACSS2 INHIBITORS AND METHODS OF USE THEREOF
  申请人：Metabomed Ltd

  公开号：EP3983386A1

  公开（公告）日：2022-04-20
• [EN] ACSS2 INHIBITORS AND METHODS OF USE THEREOF<br/>[FR] INHIBITEURS D'ACSS2 ET LEURS PROCÉDÉS D'UTILISATION
  申请人：METABOMED LTD

  公开号：WO2020230136A1

  公开（公告）日：2020-11-19

  The present invention relates to novel ACSS2 inhibitors having activity as anti-cancer therapy, treatment of alcoholism, and viral infection (e.g., CMV), composition and methods of preparation thereof, and uses thereof for treating viral infection, alcoholism, alcoholic steatohepatitis (ASH), non-alcoholic steatohepatitis (NASH), obesity/weight gain, anxiety, depression, post-traumatic stress disorder, inflammatory/autoimmune conditions and cancer, including metastatic cancer, advanced cancer, and dmg resistant cancer of various types.
• Targeting Inactive Enzyme Conformation: Aryl Diketoacid Derivatives as a New Class of PTP1B Inhibitors
  作者：Sijiu Liu、Li-Fan Zeng、Li Wu、Xiao Yu、Ting Xue、Andrea M. Gunawan、Ya-Qiu Long、Zhong-Yin Zhang

  DOI：10.1021/ja8068177

  日期：2008.12.17

  There has been considerable interest in protein tyrosine phosphatase 1B (PTP1B) as a therapeutic target for diabetes, obesity, as well as cancer. Identifying inhibitory compounds with good bioavailability is a major challenge of drug discovery programs targeted toward PTPs. Most current PTP active site-directed pharmacophores are negatively charged pTyr mimetics which cannot readily enter the cell. This lack of cell permeability limits the utility of such compounds in signaling studies and further therapeutic development. We identify aryl diketoacids as novel pTyr surrogates and show that neutral amide-linked aryl diketoacid dimers also exhibit excellent PTP inhibitory activity. Kinetic studies establish that these aryl diketoacid derivatives act as noncompetitive inhibitors of PTP1B. Crystal structures of ligand-bound PTP1B reveal that both the aryl diketoacid and its dimeric derivative bind PTP1B at the active site, albeit with distinct modes of interaction, in the catalytically inactive, WPD loop open conformation. Furthermore, dimeric aryl diketoacids are cell permeable and enhance insulin signaling in hepatoma cells, suggesting that targeting the inactive conformation may provide a unique opportunity for creating active site-directed PTP1B inhibitors with improved pharmacological properties.